Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...

Related Keywords

United States ,Berlin ,Germany ,American ,Sarah Cavanaugh ,Allen Kaplan ,Anthonys Marucci ,Marcus Maurer ,Corporate Affairs Administration ,Company Contact ,Company Phase ,Celldex Therapeutics Inc ,Nasdaq ,American Academy Of Allergy ,Globenewswire Inc ,Celldex Therapeutics ,Annual Meeting ,Chief Executive Officer ,Clinical Activity Assessments ,Confidence Interval ,Complete Control ,Private Securities Litigation Reform Act ,Vice President ,Corporate Affairs ,Markets ,